Abstract
Successes and Challenges of PARP Inhibitors in Cancer Therapy.
Highlights
Successes and challenges of Poly (ADP-ribose) polymerases (PARPs) inhibitors in cancer therapyTiffany K. Ricks*, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul Kluetz and Richard Pazdur Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S Food and Drug Administration, Silver Spring, MD, USA Keywords: PARP inhibitor, cancer, drug resistance, BRCA1, BRCA2, homologous recombination Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology Citation: Ricks TK, Chiu H-J, Ison G, Kim G, McKee AE, Kluetz P and Pazdur R (2015) Successes and challenges of PARP inhibitors in cancer therapy. Front. Oncol. 5:222
(ADP-ribose) polymerases (PARPs) are a family of enzymes involved in cellular homeostasis, including DNA transcription, cell-cycle regulation, and DNA repair [1, 2]
In the absence of Poly (ADP-ribose) polymerases (PARPs) activity, unrepaired SSBs can lead to more deleterious double strand breaks (DSBs), which require high fidelity, homologous recombination (HR) or low fidelity, non-homologous end joining (NHEJ) for repair
Summary
Tiffany K. Ricks*, Haw-Jyh Chiu, Gwynn Ison, Geoffrey Kim, Amy E. McKee, Paul Kluetz and Richard Pazdur Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S Food and Drug Administration, Silver Spring, MD, USA Keywords: PARP inhibitor, cancer, drug resistance, BRCA1, BRCA2, homologous recombination Specialty section: This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology Citation: Ricks TK, Chiu H-J, Ison G, Kim G, McKee AE, Kluetz P and Pazdur R (2015) Successes and challenges of PARP inhibitors in cancer therapy. Front. Oncol. 5:222.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
